You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥與百濟神州(06160.HK)開展臨床開發合作
阿思達克 05-26 15:35
和黃醫藥今日宣佈與百濟神州(06160.HK)簽訂一項臨床開發合作協議,在美國、歐洲、中國和澳洲開展臨床試驗,以評估和黃醫藥的候選藥物——索凡替尼和(口夫)(口奎)替尼,與百濟神州的抗程序性死亡受體1(PD-1)抗體——替雷利珠單抗聯合治療各種實體瘤的安全性、耐受性和療效。

根據協議條款,和黃醫藥與百濟神州分別計劃在不同適應症及地區進行索凡替尼與替雷利珠單抗,或(口夫)(口奎)替尼與替雷利珠單抗聯合療法的開發。雙方已同意相互提供研究藥物及其他方面支持。目前,這三種化合物均在中國以外許多國家進行晚期全球臨床開發。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account